These findings suggest that the combined administration of targeted PUMA and FASN inhibitors is a promising therapeutic strategy, validating our mechanistic insights and offering a potential path forward in ccRCC treatment. Here, BBC3 is linked to nonpapillary renal cell carcinoma.